ey0021.12-6 | Improving T2D Outcomes | ESPEYB21
WT Garvey
, JP Frias
, AM Jastreboff
, CW le Roux
, N Sattar
, D Aizenberg
, H Mao
, S Zhang
, NN Ahmad
, MC Bunck
, I Benabbad
, XM; SURMOUNT-2 investigators. Zhang
Brief Summary: This double-blind, placebo-controlled international trial, randomized overweight and obese adults with T2D to either once-weekly subcutaneous Tirzepatide (10 mg or 15 mg) or placebo for 72 weeks. Tirzepatide led to weight reductions of -9.6% with the 10 mg dose and -11.6% with the 15 mg dose, compared to placebo. From a mean baseline 8.0%, HbA1c reduced by 2·1% with both the 10 mg, and 15 mg dose of triszepatied compared to 0·5% reduction on plac...